Hospital Pharmacy - June 2018 - 197

197

Ali et al
risk assessment criteria for patients on either R-CHOP or
CHOP in Pakistan.

Conclusion
The study highlighted the incidence of HBV and FN in
DLBCL patient receiving either CHOP or R-CHOP therapy.
All the patients undergoing either treatment should be
screened for HBV (HBcAg, HBsAg, and HBsAg titer) to
establish their pretreatment status. Besides, this screening
will help to decide about prophylactic antiviral therapy and
will also help to delineate between the patients who had reactivation of HBV or had acquired de novo new infection as a
result of chemotherapy. Moreover, prophylactic treatment
with G-CSF should also be taken into the equation after evaluating all the risk factor reported to increase the incidence of
FN in DLBCL patients on either treatment regimen.
Unfortunately, this is not the practice in our setup. Hopefully,
our study will help to improve the current management
practices for DLBCL patients.
Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with respect
to the research, authorship, and/or publication of this article.

Funding

10.

11.

12.

The author(s) received no financial support for the research, authorship, and/or publication of this article.

References
1. Ganem D, Prince AM. Hepatitis B virus infection-
natural history and clinical consequences. N Engl J Med.
2004;350(11):1118-1129.
2. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology.
2007;45(2):507-539.
3. Lok AS, Lai CL, Wu PC, Wong VC, Yeoh EK, Lin HJ.
Hepatitis B virus infection in Chinese families in Hong Kong.
Am J Epidemiol. 1987;126(3):492-499.
4. Rehermann B, Ferrari C, Pasquinelli C, Chisari FV. The hepatitis B virus persists for decades after patients' recovery from
acute viral hepatitis despite active maintenance of a cytotoxic
T-lymphocyte response. Nat Med. 1996;2(10):1104-1118.
5. Coiffier B, Lepage E, Brière J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly

13.

14.

15.

16.

patients with diffuse large-B-cell lymphoma. N Engl J Med.
2002;346(4):235-242.
Pfreundschuh M, Trümper L, Österborg A, et al. CHOP-like
chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse
large-B-cell lymphoma: a randomised controlled trial by the
MabThera International Trial (MInT) Group. Lancet Oncol.
2006;7(5):379-391.
Habermann TM, Weller EA, Morrison VA, et al. RituximabCHOP versus CHOP alone or with maintenance rituximab
in older patients with diffuse large B-cell lymphoma. J Clin
Oncol. 2006;24(19):3121-3127.
Aksoy S, Harputluoglu H, Kilickap S, et al. Rituximab-related
viral infections in lymphoma patients. Leuk Lymphoma.
2007;48(7):1307-1312.
Targhetta C, Cabras MG, Mamusa AM, Mascia G, Angelucci
E. Hepatitis B virus-related liver disease in isolated
anti-hepatitis B-core positive lymphoma patients receiving chemo-or chemo-immune therapy. Haematologica.
2008;93(6):951-952.
Niscola P, Del Principe MI, Maurillo L, et al. Fulminant B hepatitis in a surface antigen-negative patient with B-cell chronic
lymphocytic leukaemia after rituximab therapy. Leukemia.
2005;19(10):1840-1841.
Salar A, Haioun C, Rossi FG, et al. Febrile neutropenia risk
assessment and granulocyte-colony stimulating factor support in patients with diffuse large B cell lymphoma receiving
R-CHOP regimens.
Crawford J, Dale DC, Lyman GH. Chemotherapy-induced
neutropenia: risks, consequences, and new directions for
its management [published correction appears in Cancer.
2004;100(9):1993-1994]. Cancer. 2004;100(2):228-237.
Perceau G, Diris N, Estines O, Derancourt C, Lévy S, Bernard
P. Late lethal hepatitis B virus reactivation after rituximab treatment of low-grade cutaneous B-cell lymphoma. Br J Dermatol.
2006;155(5):1053-1056.
Yeo W, Chan TC, Leung NW, et al. Hepatitis B virus reactivation
in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol.
2008;27(4):605-611.
Choi YW, Jeong SH, Ahn MS, et al. Patterns of neutropenia
and risk factors for febrile neutropenia of diffuse large B-cell
lymphoma patients treated with rituximab-CHOP. J Korean
Med Sci. 2014;29(11):1493-1500.
Lanini S, Molloy AC, Fine PE, Prentice AG, Ippolito G,
Kibbler CC. Risk of infection in patients with lymphoma
receiving rituximab: systematic review and meta-analysis.
BMC Med. 2011;9(1):36.

Table of Contents for the Digital Edition of Hospital Pharmacy - June 2018